Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Conmed (DE:EC8)
FRANKFURT:EC8
Conmed (EC8) Stock Price & Analysis
1 Followers
EC8 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€57.50 - €124.24
Previous Close€69.5
Volume0.00
Average Volume (3M)15.00
Market Cap
€2.17B
Enterprise Value€3.07B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$973.85M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Jul 24, 2024EPS Estimate
€0.84Next Dividend Ex-Date
Jun 14, 2024Dividend Yield1.05%
Share Statistics
EPS (TTM)N/A
Shares Outstanding30,800,747
10 Day Avg. Volume0
30 Day Avg. Volume15
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-3.78
Price to Sales (P/S)1.72
Price to Cash Flow (P/CF)10.40
P/FCF Ratio9.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.46
Enterprise Value/Gross Profit4.53
Enterprise Value/Ebitda15.56
Forecast
1Y Price Target
€80.90Price Target Upside16.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Conmed News
PremiumCompany Announcements
Conmed Announces Executive Transition and New Officer Compensation
PremiumCompany Announcements
Conmed Announces Executive Leadership Changes and Compensation Updates
Bulls Say, Bears Say
Bulls Say
Market GrowthThe estimated market opportunity for BioBrace is expected to grow substantially, indicating a promising future for the product's sales and market share.
Product InnovationBioBrace's design enhances the quality and durability of tendon/ligament repair, potentially preventing retears and optimizing healing, which could increase its adoption in surgeries.
Regulatory MilestoneThe FDA 510(k) clearance of the fifth-generation robotic system represents a significant regulatory milestone, highlighting advancements in technology and potential for increased adoption in surgical procedures.
Bears Say
Financial GuidanceManagement lowered their revenue and EPS guidance due to a $10M incremental currency headwind and higher interest expense.
Growth ConcernsOrganic revenue growth slowed to 5.9% Y/Y in 1Q24 from 31.5% in 4Q23.
Product CompetitionInvestor concerns center on competition from the recently FDA-approved DV5 with a built-in insufflator, which may impact CNMD's market position.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
36.19% Other Institutional Investors
63.81% Public Companies and
Individual Investors
EC8 FAQ
What was Conmed’s price range in the past 12 months?
Conmed lowest stock price was €57.50 and its highest was €124.24 in the past 12 months.
What is Conmed’s market cap?
Currently, no data Available
When is Conmed’s upcoming earnings report date?
Conmed’s upcoming earnings report date is Jul 24, 2024 which is in 51 days.
How were Conmed’s earnings last quarter?
Conmed released its earnings results on Apr 24, 2024. The company reported €0.728 earnings per share for the quarter, beating the consensus estimate of €0.68 by €0.048.
Is Conmed overvalued?
According to Wall Street analysts Conmed’s price is currently Undervalued.
Does Conmed pay dividends?
Conmed pays a Quarterly dividend of €0.18 which represents an annual dividend yield of 1.05%. See more information on Conmed dividends here
What is Conmed’s EPS estimate?
Conmed’s EPS estimate is €0.84.
How many shares outstanding does Conmed have?
Currently, no data Available
What happened to Conmed’s price movement after its last earnings report?
Conmed reported an EPS of €0.728 in its last earnings report, beating expectations of €0.68. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Conmed?
Among the largest hedge funds holding Conmed’s share is Deerfield Management Company, LP. It holds Conmed’s shares valued at 27M.
---
Conmed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€80.90 (16.40% Upside)
€80.90 (16.40% Upside)
Blogger Sentiment
Bullish
DE:EC8 Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $544.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.51%
12-Months-Change
Fundamentals
Return on Equity
10.25%
Trailing 12-Months
Asset Growth
-0.47%
Trailing 12-Months
Company Description
Conmed
CONMED Corp. operates as a medical technology company, which engages in the development, manufacture and sale of surgical devices and related equipment. It operates through the following geographical segments: United States; Americas excluding the United States; Europe, Middle East, and Africa; and Asia Pacific. Its product lines also include orthopedic surgey and general surgery. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Utica, NY.
---
EC8 Company Deck
---
EC8 Earnings Call
Q1 2024
0:00 / 0:00
---
EC8 Stock 12 Month Forecast
Average Price Target
€80.90
▲(16.40% Upside)
Technical Analysis
Conmed
―
Merit Medical Systems
―
Abbott Laboratories
―
Intuitive Surgical
―
Becton Dickinson
―
Best Analysts Covering EC8
1 Year
1 Year Success Rate
10/21 ratings generated profit
1 Year Average Return
+5.96%
reiterated a buy rating last month
Copying Rick Wise's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +5.96% per trade.
---